ClinicalTrials.gg
CompletedNCT05717686Updated Feb 14, 2025

A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B

A Phase 1 interventional study of AHB-137 injection and Placebo in Chronic Hepatitis B, sponsored by AusperBio Therapeutics Inc.. Completed at 9 sites in 4 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-14.

Sponsored by AusperBio Therapeutics Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic — 6 open to participants now, 8 under way, 1 of them phase 3. Hepatitis B Virus Antisense Oligonucleotide AHB-137 · Hepatitis B, Chronic.

Enrollment
9th of 11
64 · median 86
Started
2023
with 1 other
Phase 1
2 of 11
1 open now
Registered
1st of 11
by date
Lead sponsor
3 of 11
AusperBio Therapeutics Inc.

Among the 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic, this one is the 9th largest by enrollment, is one of 2 that started in 2023, is one of 2 in phase 1, and was the 1st registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

6 of the 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About Hepatitis B Virus Antisense Oligonucleotide AHB-137

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 subcutaneous injection in healthy volunteers and in chronic hepatitis B (CHB) patients after single and multiple doses. In addition, the study will evaluate the initial antiviral efficacy of AHB-137 in CHB patients following a multiple dosing regimen.

Read the detailed description

This is a first-in-human study of AHB-137, consisting of four parts. Parts A and B are randomized, double-blinded, placebo-controlled studies designed to assess the safety, tolerability, pharmacokinetics of AHB-137 following subcutaneous injection in healthy volunteers at a 6:2 ratio of AHB-137 to placebo. Part A is a single-ascending dose (SAD) study, and Part B is a single-ascending dose (SAD) study, and Part B is a multiple dose (MD) study. Part C is an open label MD study with up to 6 CHB patients. Part D is a double blinded study in CHB patients at a 4:1 ratio to receive AHB-137 or placebo.

Study advancement to subsequent parts/cohorts will require satisfactory interim reviews of available cumulative safety data by the Safety Review Committees (SRC), using the safety criteria and review procedures described in the protocol.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants are required to meet all the following inclusion criteria in order to be enrolled in the study:

    1. 18-65 years old male or female.
    2. (BMI) between 19 to 35 kg/m2 (inclusive) and body weight equal to or over 45 kg.
    3. Participants' COVID-19 PCR test should be negative during screening.
    4. Participants' COVID-19 Rapid Antigen Test (RAT) should be negative at check-in.
  • CHB patients are required to meet all the following inclusion criteria in order to be enrolled in the study:

    1. Have given written (signed and dated) and any authorizations required by local law and is able to comply with all study requirements.
    2. Age 18 to 65 years old.
    3. ≤ 5 for CHB patients recruited to Part C; ALT ≤ 2 ULN for CHB patients recruited to Part D.
    4. CHB patients who have documented chronic infection equal to or above 6 months prior to screening. Otherwise, CHB patients need to be HBsAg positive and IgM HBcAb negative.
    5. CHB patients participating in Part D should have been on commercially available HBV OAV treatment(s) for at least 6 months with no change in regimen for 3 months prior to screening. HBV DNA under limit of quantification (LOQ) at Screening.
    6. Both HBeAg positive and negative CHB patients can be recruited to Part C of the study. Only HBeAg negative CHB patients can be recruited to Part D of the study.
    7. COVID-19 RAT test should be negative at check-in.

Exclusion criteria

Exclusion Criteria:

  • Healthy participants are required to not meet any of the following exclusion criteria in order to be enrolled in the study:

    1. Pregnant (positive pregnancy test) or lactating women. Male participants without using proper (e.g. condom) with partners who are pregnant or lactating.
    2. History or symptoms of any gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardio-vascular, endocrinological, hematological or allergic disease, metabolic disorder, cancer or cirrhosis.
    3. Personal history of congenital long syndrome or family history of sudden cardiac death.
    4. Any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug, or multiple drug allergies (non-active hay fever is acceptable).
    5. Any clinically significant concomitant diseases or condition that could interfere with, or treatment of which might interfere with, the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the participant in this study.
    6. Clinically relevant (ECG) abnormalities on screening ECG.
    7. ECG with QRS and/or T-wave judged to be unfavorable for a consistently accurate QT measurement.
    8. (CrCl) cutoff ≤ 60 ml/min (using the Cockcroft-Gault formula).
    9. Positive test at screening of any of the following: hepatitis A (HAV IgM Ab), (HBsAg), (HCV RNA or HCV Ab), 1 and 2 (HIV Ab), or TP-Ab.
    10. Any other clinically significant abnormalities in laboratory test results at screening. In the case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility.
    11. History of bleeding diathesis or coagulopathy.

CHB patients are required to not meet any of the following exclusion criteria in order to be enrolled in the study:

  1. History of liver cirrhosis and/or evidence of cirrhosis as determined by any 1 of the following:

    1. Liver (i.e., Metavir Score F4) within 2 years of screening, or
    2. FibroScan > 12 KPa, within 12 months of screening, or
    3. -to- Index (APRI) > 2 and FibroSure result > 0.7 within 12 months of screening.

    For patients without a test for cirrhosis in the above timeframes, FibroScan, or APRI and FibroSure, may be performed during the screening period to rule out cirrhosis History of liver failure as evidenced by ascites, hepatic encephalopathy, and/or gastric or esophageal varices.

  2. History of liver disease other than hepatitis B.
  3. Co-infection with TP, HCV, HIV, or hepatitis D virus (HDV).
  4. >35 kg/m2 .
  5. History or suspected presence of vasculitis .
  6. Diagnosed hepatocellular carcinoma or suspected hepatocellular carcinoma as evidenced by screening alpha-fetoprotein ≥200 ng/mL. If the screening alpha-fetoprotein is ≥50 ng/mL and \<200 ng/mL, the absence of liver mass must be documented by imaging within 6 months before randomization.
  7. Clinically relevant electrocardiogram (ECG) abnormalities on screening ECG.
  8. Screening laboratory results as follows, or any other clinically significant abnormalities in screening laboratory values that would render a patient unsuitable for inclusion.

    1. ALT > 5 x for Part C or > 2 x ULN for Part D
    2. Total > 1.25 x ULN
    3. Serum albumin \< 3.4 g/dL
    4. of prothrombin time > 1.25
    5. Platelet count \<140 x 10\^9/L
    6. \<12.0 g/dL for males and \<11.0 g/dL for females
    7. White blood cell count \<3.0 k/mm3
    8. Serum creatinine >1.1 x ULN
    9. Urine protein/creatinine ratio ≥0.2 mg/mg. In the event of a ratio above this threshold, eligibility may be confirmed by a quantitative total urine protein measurement of \<150 mg/24 hour
    10. Positive test (including trace) for blood on urinalysis. In the event of a positive test, eligibility may be confirmed with urine microscopy showing \<5 red blood cells per high power field
  9. Clinically significant abnormalities and/or poorly controlled medical conditions (e.g. Cardiovascular, pulmonary, metabolic disease) in the opinion of the investigator.
  10. History of bleeding diathesis or coagulopathy.
  11. History of extrahepatic disorders possibly related to HBV immune complexes (e.g., glomerulonephritis, polyarteritis nodosa) .
  12. Active infection other than HBV, requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Study Day 1.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Part A: SAD in healthy participants

    Part A: Single ascending doses of up to 450 mg AHB-137 by subcutaneous (SC) injection in healthy participants.

    Drug: AHB-137 injection · Drug: Placebo

  • Experimental
    Part B: MD in healthy participants

    Part B: Multiple doses of 300 mg AHB-137 by subcutaneous (SC) injection in healthy participants.

    Drug: AHB-137 injection · Drug: Placebo

  • Experimental
    Part C: MD in CHB patients (open label)

    Part C: Multiple doses of 300 mg AHB-137 by subcutaneous (SC) injection in CHB patients.

    Drug: AHB-137 injection

  • Experimental
    Part D: MD in CHB patients in multiple centers

    Part D: Multiple doses of 200 mg or 300 mg AHB-137 by subcutaneous (SC) injection in CHB patients (Multiple centers across multiple regions).

    Drug: AHB-137 injection · Drug: Placebo

Interventions

  • AHB-137 will be administered

  • DrugPlacebo

    Placebo will be administered

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With Treatment-Emergent Adverse Events (TEAEs) in Healthy Volunteers

    Time frame: Up to 30 days for SAD, up to 113 days for MD

  2. Proportion of Participants With Treatment-Emergent Adverse Events (TEAEs) in CHB patients

    Time frame: Up to 204 days for MD

Secondary outcomes

  1. The anti-HBV efficacy of AHB-137: evaluate the change in serum HBsAg (log10 IU/mL) from baseline.

    Time frame: Up to 204 days

  2. The anti-HBV efficacy of AHB-137: evaluate the expression of HBsAb in serum.

    Time frame: Up to 204 days

  3. The pharmacokinetic profile of AHB-137: the maximum observed plasma concentration (Cmax) of AHB-137

    Time frame: Up to 30 days for SAD; up to 204 days for MD

  4. The pharmacokinetic profile of AHB-137: time of observed maximal concentration (Tmax) of AHB-137

    Time frame: Up to 30 days for SAD; up to 204 days for MD

  5. The pharmacokinetic profile of AHB-137: areas under the concentration time curve (AUC) of AHB-137

    Time frame: Up to 30 days for SAD; up to 204 days for MD

  6. The pharmacokinetic profile of AHB-137: mean residence time (MRT) of AHB-137

    Time frame: Up to 30 days for SAD; up to 204 days for MD

  7. The pharmacokinetic profile of AHB-137: terminal half-life (t1/2) of AHB-137

    Time frame: Up to 30 days for SAD; up to 204 days for MD

  8. The pharmacokinetic profile of AHB-137: apparent subcutaneous plasma clearance (CL/F) of AHB-137

    Time frame: Up to 30 days for SAD; up to 204 days for MD

  9. The pharmacokinetic profile of AHB-137: amount of AHB-137 excreted in urine (Ae)

    Time frame: Day 1-4 for SAD; Day 1-4 and Day 22-25 for MD

  10. The pharmacokinetic profile of AHB-137: renal clearance (CLr) of AHB-137

    Time frame: Day 1-4 for SAD; Day 1-4 and Day 22-25 for MD

07

Study locations

9 sites
  • Stanford Medicine
    Redwood City, California 94063, United States
  • University of Maryland Baltimore
    Baltimore, Maryland 21201, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • American Research Corporation
    Houston, Texas 78215, United States
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • New Zealand Clinical Research
    Grafton, Auckland 1010, New Zealand
  • Chia-Yi Christian Hospital
    Chiayi City, 60002, Taiwan
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung, 80756, Taiwan
  • E-DA Hospital
    Kaohsiung, 82445, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Jan 2025, 22 months.

Of 73 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 22 months is above that.

Counting every sponsor, half of 81 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2023
First posted
Feb 8, 2023
StartActual
Feb 28, 2023
Primary completionActual
Jan 7, 2025
CompletionActual
Jan 7, 2025
Last update
Feb 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05717686
Lead sponsor
AusperBio Therapeutics Inc.
Responsible party
Sponsor
First posted
Feb 8, 2023
Start date
Feb 28, 2023
Primary completion
Jan 7, 2025
Completion
Jan 7, 2025
Last update
Feb 14, 2025

Study contacts

Ed Gane
principal investigator · University of Auckland, New Zealand

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hepatitis B Virus Antisense Oligonucleotide AHB-137

Start the discussion